In the context of managing treatment-resistant depression in individuals characterized by elevated baseline inflammatory markers, Infliximab, an anti-TNF-α antibody primarily indicated for autoimmune inflammatory conditions, has demonstrated the capacity to alleviate depressive symptoms [285]. The gene discussed is TNF; the disease is depressive disorder.